Novavax Inc.’s shares plunged nearly 20 percent in premarket trading on May 10 due to uncertainty over global demand for the company’s COVID-19 vaccine following a slow start to deliveries.

Shares of Adaptive Biotechnologies climbed on March 9 after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12 percent. 

Shares of Cassava Sciences were up more than 5% in premarket trading on February 11 after the U.S. Food and Drug Administration denied a Citizen Petition filed during 2021 on behalf of short-selling clients who sought to suspend the company’s Alzheimer’s clinical trials.

Shares of Madrigal Pharmaceuticals went up in trading after the company announced positive topline data from a Phase III assessment of resmetirom in non-alcoholic fatty liver disease.

Shares of Applied Therapeutics plunged in premarket trading on January 3 after the company announced it is unable to seek regulatory approval of the Galactosemia therapeutic AT-007 at this time.

Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.

Florida-based AzurRx BioPharma is bolstering the company’s gastrointestinal disease pipeline with the $229 million acquisition of First Wave Bio and its small molecule therapeutics for auto-immune inflammatory bowel diseases (IBD) and other serious conditions.

Lomecel-B – Longeveron’s proprietary off-the-shelf cell therapy for aging frailty – failed the six-minute walk test (6MWT) endpoint of a Phase IIb study, according to a statement published by the Miami-based biotech on Aug. 13.

Topline results from Outlook Therapeutics’ pivotal Phase III NORSE TWO safety and efficacy trial show the biopharmaceutical company’s ONS-5010/Lytenava (bevacizumab) significantly improved outcomes in patients with neovascular age-related macular degeneration.

The U.S. Food and Drug Administration rejected Ardelyx Inc.’s chronic kidney disease drug tenapanor by issuing a Complete Response Letter.